Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply

被引：1
|
作者：
Bernal, T. [1 ]
Martinez-Camblor, P. [1 ,2 ]
Sanchez-Garcia, J. [3 ]
Sanz, G. [4 ]
机构：
[1] Univ Oviedo, Hosp Univ Cent Asturias, Dept Med, Oviedo, Spain
[2] Univ Autonoma Chile, Santiago, Chile
[3] Univ Cordoba, Hosp Univ Reina Sofia, IMIBIC, Cordoba, Spain
[4] Hosp Univ & Politecn La Fe, Valencia, Spain
来源：
LEUKEMIA | 2016年 / 30卷 / 03期
关键词：
REGISTRY;
D O I：
10.1038/leu.2015.339
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：740 / 741
页数：2
相关论文
共 50 条
  • [1] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors’ reply
    T Bernal
    P Martínez-Camblor
    J Sánchez-García
    G Sanz
    [J]. Leukemia, 2016, 30 : 740 - 741
  • [2] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    Dinmohamed, A. G.
    van Norden, Y.
    van de Loosdrecht, A. A.
    Jongen-Lavrencic, M.
    [J]. LEUKEMIA, 2016, 30 (08) : 1795 - +
  • [3] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    A G Dinmohamed
    Y van Norden
    A A van de Loosdrecht
    M Jongen-Lavrencic
    [J]. Leukemia, 2016, 30 : 1795 - 1796
  • [4] Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes
    Levy, A. R.
    Zou, D.
    Risebrough, N.
    Buckstein, R.
    Kim, T.
    Brereton, N.
    [J]. CURRENT ONCOLOGY, 2014, 21 (01) : E29 - E40
  • [5] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
    A G Dinmohamed
    Y van Norden
    O Visser
    E F M Posthuma
    P C Huijgens
    P Sonneveld
    A A van de Loosdrecht
    M Jongen-Lavrencic
    [J]. Leukemia, 2015, 29 : 2449 - 2451
  • [6] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
    Dinmohamed, A. G.
    van Norden, Y.
    Visser, O.
    Posthuma, E. F. M.
    Huijgens, P. C.
    Sonneveld, P.
    van de Loosdrecht, A. A.
    Jongen-Lavrencic, M.
    [J]. LEUKEMIA, 2015, 29 (12) : 2449 - 2451
  • [7] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew
    Lancet, Jeffrey
    Komrokji, Rami
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
  • [8] Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes
    Rajakumaraswamy, Nishanthan
    Gandhi, Mitul
    Wei, Andrew H.
    Sallman, David A.
    Daver, Naval G.
    Mo, Shuyuan
    Iqbal, Shahed
    Karalliyadda, Roshan
    Chen, Manli
    Wang, Yunfei
    Vyas, Paresh
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04):
  • [9] Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion
    Fenaux, Pierre
    Bowen, David
    Gattermann, Norbert
    Hellstrom-Lindberg, Eva
    Hofmann, Wolf-Karsten
    Pfeilstoecker, Michael
    Sanz, Guillermo
    Santini, Valeria
    [J]. LEUKEMIA RESEARCH, 2010, 34 (11) : 1410 - 1416
  • [10] Decitabine treatment of patients with higher-risk myelodysplastic syndromes
    Steensma, David P.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S12 - S17
12345